Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee
- About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly
- The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations
- Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating psoriasis, may offer significant advantages over Apogee Therapeutics, whose recent IPO has resulted in a $1 billion market cap
- Scinai’s NanoAbs offer additional routes of administration, a higher affinity and binding to the target, and stability at room temperature – key differentiators to currently available treatments on the market today
Psoriasis is a chronic disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis. Nearly 50% of people with psoriasis experience moderate to severe symptoms (https://nnw.fm/hylz3 ). The psoriasis treatment market was valued at $16.45 billion in 2022 and is expected to grow at a CAGR of 7.8%, reaching $48.33 billion by 2030. The market’s growth is attributed to the number of patients diagnosed with psoriasis and an increasing prevalence of skin disorders in developed nations (https://nnw.fm/9emlt ).
Antibodies and nanobodies against the IL-17 (Interleukin-17) cytokine and other family cytokines are showing success in the treatment of psoriasis and associated immune diseases. Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, in collaboration with Max Planck Society and the University Medical Center Gottingen, has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.
In addition to Scinai, Apogee Therapeutics (NASDAQ: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunological indications, is also targeting IL-17 for psoriasis treatment. Apogee went public in July 2023 at $500 million pre-money, raising $300 million in an upsized deal, and now exceeds a $1 billion market cap.
Both companies are currently in the pre-clinical stage of development – but Scinai believes that its NanoAbs exhibit multiple advantages over Apogee’s product, including:
- Being amenable to new routes of administration – including inhalation and intradermal injection, neither of which work with regular antibodies. Scinai’s NanoAbs potentially create a new market opportunity that does not directly compete with other companies with existing antibody treatments by targeting the large, underserved population of patients with mild to moderate psoriasis.
- Higher affinity and better binding suggest that Scinai’s NanoAbs may permit lower dosages with fewer side effects by providing a higher affinity and better binding to the target, lowering the costs associated with treatment.
- Stability at room temperature – Regular antibodies require complex cold chain logistics until administered to the patient. These treatments are more expensive and limit where and when treatment can be administered, leading to high spoilage. Scinai’s NanoAbs are stable at room temperature, expanding the opportunity for administration and reducing spoilage.
Scinai’s alpaca-derived NanoAbs offer a significant advantage to the underserved population, especially those with mild to moderate psoriasis. Its product potentially offers advantages that Apogee’s product cannot and significantly enhances the route of administration, binding to the target, and an increased window of administration.
The company’s leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb. It has built, owns, and operates a 20,000-square-foot state-of-the-art GMP biologics manufacturing facility that houses laboratories, production facilities, and offices, giving the company a unique advantage in the industry.
For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly
- The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations
- Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating psoriasis, may offer significant advantages over Apogee Therapeutics, whose recent IPO has resulted in a $1 billion market cap
- Scinai’s NanoAbs offer additional routes of administration, a higher affinity and binding to the target, and stability at room temperature – key differentiators to currently available treatments on the market today
Psoriasis is a chronic disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis. Nearly 50% of people with psoriasis experience moderate to severe symptoms (https://nnw.fm/hylz3 ). The psoriasis treatment market was valued at $16.45 billion in 2022 and is expected to grow at a CAGR of 7.8%, reaching $48.33 billion by 2030. The market’s growth is attributed to the number of patients diagnosed with psoriasis and an increasing prevalence of skin disorders in developed nations (https://nnw.fm/9emlt ).
Antibodies and nanobodies against the IL-17 (Interleukin-17) cytokine and other family cytokines are showing success in the treatment of psoriasis and associated immune diseases. Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, in collaboration with Max Planck Society and the University Medical Center Gottingen, has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.
In addition to Scinai, Apogee Therapeutics (NASDAQ: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunological indications, is also targeting IL-17 for psoriasis treatment. Apogee went public in July 2023 at $500 million pre-money, raising $300 million in an upsized deal, and now exceeds a $1 billion market cap.
Both companies are currently in the pre-clinical stage of development – but Scinai believes that its NanoAbs exhibit multiple advantages over Apogee’s product, including:
- Being amenable to new routes of administration – including inhalation and intradermal injection, neither of which work with regular antibodies. Scinai’s NanoAbs potentially create a new market opportunity that does not directly compete with other companies with existing antibody treatments by targeting the large, underserved population of patients with mild to moderate psoriasis.
- Higher affinity and better binding suggest that Scinai’s NanoAbs may permit lower dosages with fewer side effects by providing a higher affinity and better binding to the target, lowering the costs associated with treatment.
- Stability at room temperature – Regular antibodies require complex cold chain logistics until administered to the patient. These treatments are more expensive and limit where and when treatment can be administered, leading to high spoilage. Scinai’s NanoAbs are stable at room temperature, expanding the opportunity for administration and reducing spoilage.
Scinai’s alpaca-derived NanoAbs offer a significant advantage to the underserved population, especially those with mild to moderate psoriasis. Its product potentially offers advantages that Apogee’s product cannot and significantly enhances the route of administration, binding to the target, and an increased window of administration.
The company’s leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb. It has built, owns, and operates a 20,000-square-foot state-of-the-art GMP biologics manufacturing facility that houses laboratories, production facilities, and offices, giving the company a unique advantage in the industry.
For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
